Optional data elements states may collect, based on specific legislative goals.A common prescription drug pricing data set that states agree should be collected.The results of this initiative - Supporting Effective State Transparency Laws - will become available for use by all states in 2019 through funding support by the Laura and John Arnold Foundation. ![]() Maine and New Hampshire are conducting studies on drug price transparency. ![]() Currently, California, Oregon, Nevada, Connecticut, and Vermont require manufacturers to report on price increases and the reasons behind those increases. This state-directed partnership will support the alignment of data collection and enable cross-state analyses. The National Academy for State Health Policy (NASHP) is partnering with Mathematica Policy Research to help states increase transparency and accountability to address rising prescription drug prices.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |